The global heart failure therapeutics market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The market is driven by factors such as increasing prevalence of heart failure, rising awareness about the disease and its treatment options, and technological advancements in the field of cardiology.
The diagnosis segment accounted for the largest share in 2018 due to increasing prevalence of heart failure globally. The prognosis segment is expected to grow at a CAGR of 6% during the forecast period owing to rising awareness about prognosis-related complications and their prevention methods among patients with heart failure. The treatment options segment accounted for the second-largest share in 2018 due to technological advancements in this field that have led to improved therapeutic efficacy and reduced side effects associated with treatments for heart failure.
-The global market for heart failure therapeutics is expected to grow at a CAGR of 4.2% from 2017 to 2022, reaching $14.5 billion by 2022.
-The key factors driving this growth are an aging population, increasing prevalence of cardiovascular diseases, and the introduction of new drugs in the market.
-In addition, there are many opportunities for new drug development in this area as there are no approved treatments for all stages of heart failure yet.
-There is also an increased focus on prevention and management strategies such as lifestyle changes and medication adherence which will drive growth in this market over the next few years.
Industry Growth Insights published a new data on “Heart Failure Therapeutics Market”. The research report is titled “Heart Failure Therapeutics Market research by Types (Diagnosis, Prognosis, Treatment Options and Treatment Algorithm), By Applications (Hospital, Clinic, Medical Research Organization), By Players/Companies Bayer, Cynokinetics, Les Laboratoires Servier, Merck & Co., Novartis, Procoralan, Bristol-Myers Squibb Company, Cardiorentis AG, CVie Therapeutics Limited, Orion Corporation, PhaseBio Pharmaceuticals, Market Segment by Product Type, B-Blockers, Calcium Channel Blockers, Cardiac Glycosides, Diuretics, Morphine, Vasodilators/Nitrates”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Heart Failure Therapeutics Market Research Report
By Type
Diagnosis, Prognosis, Treatment Options and Treatment Algorithm
By Application
Hospital, Clinic, Medical Research Organization
By Companies
Bayer, Cynokinetics, Les Laboratoires Servier, Merck & Co., Novartis, Procoralan, Bristol-Myers Squibb Company, Cardiorentis AG, CVie Therapeutics Limited, Orion Corporation, PhaseBio Pharmaceuticals, Market Segment by Product Type, B-Blockers, Calcium Channel Blockers, Cardiac Glycosides, Diuretics, Morphine, Vasodilators/Nitrates
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
247
Number of Tables & Figures
173
Customization Available
Yes, the report can be customized as per your need.
Global Heart Failure Therapeutics Market Report Segments:
The global Heart Failure Therapeutics market is segmented on the basis of:
Types
Diagnosis, Prognosis, Treatment Options and Treatment Algorithm
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospital, Clinic, Medical Research Organization
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bayer
- Cynokinetics
- Les Laboratoires Servier
- Merck & Co.
- Novartis
- Procoralan
- Bristol-Myers Squibb Company
- Cardiorentis AG
- CVie Therapeutics Limited
- Orion Corporation
- PhaseBio Pharmaceuticals
- Market Segment by Product Type
- B-Blockers
- Calcium Channel Blockers
- Cardiac Glycosides
- Diuretics
- Morphine
- Vasodilators/Nitrates
Highlights of The Heart Failure Therapeutics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Diagnosis
- Prognosis
- Treatment Options and Treatment Algorithm
- By Application:
- Hospital
- Clinic
- Medical Research Organization
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Heart Failure Therapeutics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Heart failure therapeutics is a term used to describe the various treatments and medications that are used to improve heart function in patients with heart failure. These treatments can include medications, devices, and procedures.
Some of the major players in the heart failure therapeutics market are Bayer, Cynokinetics, Les Laboratoires Servier, Merck & Co., Novartis, Procoralan, Bristol-Myers Squibb Company, Cardiorentis AG, CVie Therapeutics Limited, Orion Corporation, PhaseBio Pharmaceuticals, Market Segment by Product Type, B-Blockers, Calcium Channel Blockers, Cardiac Glycosides, Diuretics, Morphine, Vasodilators/Nitrates.
The heart failure therapeutics market is expected to grow at a compound annual growth rate of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Heart Failure Therapeutics Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Heart Failure Therapeutics Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Heart Failure Therapeutics Market - Supply Chain
4.5. Global Heart Failure Therapeutics Market Forecast
4.5.1. Heart Failure Therapeutics Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Heart Failure Therapeutics Market Size (000 Units) and Y-o-Y Growth
4.5.3. Heart Failure Therapeutics Market Absolute $ Opportunity
5. Global Heart Failure Therapeutics Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Heart Failure Therapeutics Market Size and Volume Forecast by Type
5.3.1. Diagnosis
5.3.2. Prognosis
5.3.3. Treatment Options and Treatment Algorithm
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Heart Failure Therapeutics Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Heart Failure Therapeutics Market Size and Volume Forecast by Application
6.3.1. Hospital
6.3.2. Clinic
6.3.3. Medical Research Organization
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Heart Failure Therapeutics Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Heart Failure Therapeutics Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Heart Failure Therapeutics Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Heart Failure Therapeutics Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Heart Failure Therapeutics Demand Share Forecast, 2019-2026
9. North America Heart Failure Therapeutics Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Heart Failure Therapeutics Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Heart Failure Therapeutics Market Size and Volume Forecast by Application
9.4.1. Hospital
9.4.2. Clinic
9.4.3. Medical Research Organization
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Heart Failure Therapeutics Market Size and Volume Forecast by Type
9.7.1. Diagnosis
9.7.2. Prognosis
9.7.3. Treatment Options and Treatment Algorithm
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Heart Failure Therapeutics Demand Share Forecast, 2019-2026
10. Latin America Heart Failure Therapeutics Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Heart Failure Therapeutics Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Heart Failure Therapeutics Market Size and Volume Forecast by Application
10.4.1. Hospital
10.4.2. Clinic
10.4.3. Medical Research Organization
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Heart Failure Therapeutics Market Size and Volume Forecast by Type
10.7.1. Diagnosis
10.7.2. Prognosis
10.7.3. Treatment Options and Treatment Algorithm
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Heart Failure Therapeutics Demand Share Forecast, 2019-2026
11. Europe Heart Failure Therapeutics Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Heart Failure Therapeutics Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Heart Failure Therapeutics Market Size and Volume Forecast by Application
11.4.1. Hospital
11.4.2. Clinic
11.4.3. Medical Research Organization
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Heart Failure Therapeutics Market Size and Volume Forecast by Type
11.7.1. Diagnosis
11.7.2. Prognosis
11.7.3. Treatment Options and Treatment Algorithm
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Heart Failure Therapeutics Demand Share, 2019-2026
12. Asia Pacific Heart Failure Therapeutics Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Heart Failure Therapeutics Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Heart Failure Therapeutics Market Size and Volume Forecast by Application
12.4.1. Hospital
12.4.2. Clinic
12.4.3. Medical Research Organization
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Heart Failure Therapeutics Market Size and Volume Forecast by Type
12.7.1. Diagnosis
12.7.2. Prognosis
12.7.3. Treatment Options and Treatment Algorithm
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Heart Failure Therapeutics Demand Share, 2019-2026
13. Middle East & Africa Heart Failure Therapeutics Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Heart Failure Therapeutics Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Heart Failure Therapeutics Market Size and Volume Forecast by Application
13.4.1. Hospital
13.4.2. Clinic
13.4.3. Medical Research Organization
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Heart Failure Therapeutics Market Size and Volume Forecast by Type
13.7.1. Diagnosis
13.7.2. Prognosis
13.7.3. Treatment Options and Treatment Algorithm
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Heart Failure Therapeutics Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Heart Failure Therapeutics Market: Market Share Analysis
14.2. Heart Failure Therapeutics Distributors and Customers
14.3. Heart Failure Therapeutics Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bayer
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Cynokinetics
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Les Laboratoires Servier
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Merck & Co.
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Procoralan
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Bristol-Myers Squibb Company
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Cardiorentis AG
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. CVie Therapeutics Limited
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. Orion Corporation
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. PhaseBio Pharmaceuticals
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. Market Segment by Product Type
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. B-Blockers
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. Calcium Channel Blockers
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. Cardiac Glycosides
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. Diuretics
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. Morphine
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. Vasodilators/Nitrates
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
